

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/031,509 05/21/2002		05/21/2002	Eric Paul Krenning	0702-020040	6829	
28289	7590	05/18/2006		EXAM	EXAMINER	
		FIRM, P.C.	HUI, SAN MING R			
700 KOPPI 436 SEVEN			ART UNIT	PAPER NUMBER		
PITTSBUR				1617		
				DATE MAILED: 05/18/200	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	Application No.		Applicant(s)				
	10/031,5	09	KRENNING ET AL.						
Offic	Examine	r	Art Unit						
		San-ming		1617					
The MA Period for Reply	ILING DATE of this communica	ation appears on th	e cover sheet w	ith the correspondence a	ddress				
WHICHEVER - Extensions of time after SIX (6) MON - If NO period for re - Failure to reply wi Any reply receive	D STATUTORY PERIOD FOI IS LONGER, FROM THE MAI e may be available under the provisions of THS from the mailing date of this commun ply is specified above, the maximum statuthin the set or extended period for reply will be by the Office later than three months aften adjustment. See 37 CFR 1.704(b).	ILING DATE OF TH 37 CFR 1.136(a). In no evication. tory period will apply and w II, by statute, cause the app	HIS COMMUNI vent, however, may a r vill expire SIX (6) MON plication to become Al	CATION. reply be timely filed NTHS from the mailing date of this BANDONED (35 U.S.C. § 133).					
Status									
1)⊠ Respons	sive to communication(s) filed	on 06 March 2006	L						
2a)⊠ This acti	` · ·) This action is r							
/	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Cla	aims								
4)⊠ Claim(s) <u>53,55-58 and 60-63</u> is/are pending in the application.									
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	i) Claim(s) is/are allowed.								
6)⊠ Claim(s)	☐ Claim(s) <u>53,55-58 and 60-63</u> is/are rejected.								
7) Claim(s)	Claim(s) is/are objected to.								
8) Claim(s)	are subject to restriction	on and/or election i	requirement.						
Application Pape	rs								
9)☐ The spec	ification is objected to by the	Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority under 35	U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
1.□ C	1. Certified copies of the priority documents have been received.								
2. C	2. Certified copies of the priority documents have been received in Application No								
	ppies of the certified copies of	· ·		n received in this Nationa	al Stage				
	pplication from the Internationa								
* See the a	ttached detailed Office action	for a list of the cert	ified copies not	received.					
Attachment(s)									
1) Notice of Refere	nces Cited (PTO-892)			Summary (PTO-413)					
2) Notice of Draftsp3) Information Disc	person's Patent Drawing Review (PTC losure Statement(s) (PTO-1449 or PT	J-948) FO/SB/08)		(s)/Mail Date Informal Patent Application (P1	ГО-152)				
Paper No(s)/Mai		. =:,	6) Other:		•				

Application/Control Number: 10/031,509

Art Unit: 1617

DETAILED ACTION

Applicant's amendments filed March 6, 2006 have been entered.

Claims 53, 55-58, and 60-63 are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 53, 55-58, and 60-63 are stand rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,648,059 ('059), US 5,843,894 ('894) and Hammond et al. (Br. J. Cancer, 1993;67:1437-1439) from IDS filed April 21, 2003), for the same reason of record.

Response to Arguments

Applicant's arguments filed March 6, 2006 averring the recited transitional phrase "consisting essentially of" obviating the outstanding rejection have been fully considered but they are not persuasive. Although Hammond teaches other amnio acids to be administered, the essential active ingredients, as taught by the cited prior arts as a whole, are lysine, or polylysine, and arginine. The cited prior arts as a whole provide motivation to one of ordinary skill in the art to employ essentially lysine or polylysine with argnine. Furthermore, the dosage of the amino acids employed is taught in the

Application/Control Number: 10/031,509

Art Unit: 1617

cited prior arts. Therefore, possessing the teachings of the cited prior arts, one of ordinary skill in the art would have employed the herein claimed amino acids in a method of inhibiting renal uptake of proteins and peptides.

Applicant's arguments filed March 6, 2006 averring the cited prior arts' failure to provide motivation to co-administration of herein claimed amino acids have been considered, but are not found persuasive. The cited prior arts as a whole clearly teach what amino acids are essential in inhibiting antibodies and peptides in renal uptake. '059 even teaches the co-administration of lysine or polylysine with arginine (See claim 5). Possessing the teachings of the cited prior arts, one of ordinary skill in the art would therefore be motivated to employ the herein claimed amino acids in a method of inhibiting renal uptake of proteins and peptides, absent evidence to the contrary.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/031,509

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

San-ming Hyli Primary Examiner Art Unit 1617 Page 4